Last updated: February 20, 2026
Bivalirudin, a direct thrombin inhibitor used primarily as an anticoagulant in percutaneous coronary interventions, has a limited pool of global suppliers. It is marketed under brands like Angiomax by The Medicines Company (acquired by Novartis) and has been supplied by several contract manufacturing organizations (CMOs).
Major Commercial Suppliers
| Supplier |
Location |
Manufacturing Capacity |
Regulatory Approvals |
Market Share (Estimated) |
| The Medicines Company (Novartis) |
United States |
High |
FDA approved |
Leading supplier in the U.S. |
| Biocon |
India |
Moderate |
Approved in India, seeking global approval |
Growing presence in emerging markets |
| Contrafect Corporation |
United States |
Small-scale |
Not approved for general use |
Niche supplier for experimental formulations |
| Patheon (Thermo Fisher Scientific) |
Europe/Global |
Large contract manufacturing capacity |
Not a direct product owner |
Provides manufacturing services for various custom formulations |
Contract Manufacturing Organizations (CMOs)
Several CMOs produce bivalirudin on a contract basis, often for original manufacturers or generic companies. These include:
- Famar (Greece): Manufactures sterile injectables, including bivalirudin, for several markets.
- Samsung BioLogics (South Korea): Has capacity for peptide synthesis; potential producer for biopharmaceuticals.
- Lonza (Switzerland): Produces custom peptides and injectables under contract for pharmaceutical companies.
- WuXi Biologics (China): Offers peptide synthesis services suitable for bivalirudin.
Regulatory and Market Dynamics
- Bivalirudin's patent protection was challenged in multiple jurisdictions, leading to generic competition in some markets.
- The original patent expired in the U.S. in 2014[1], allowing for generic manufacturing.
- Supply chain reliability relies on licensed manufacturing plants compliant with Good Manufacturing Practice (GMP) standards.
Key Points on Supply Security
- Only a handful of companies have the capacity and regulatory approval to manufacture bivalirudin at scale.
- Original patent holder supplies most of the demand in North America.
- Generics and biosimilars emerging in common markets due to patent expirations.
- Contract manufacturers are used to extend supply or produce custom formulations.
Supply Risks and Market Entry Barriers
- Limited number of active GMP-certified manufacturing facilities.
- Peptide synthesis complexity increases production costs and time-to-market.
- Regulatory approval processes pose hurdles for new entrants.
- Patent and regulatory exclusivity periods restrict generic entry until expiration.
Recent Developments
- Novartis announced an intention to expand manufacturing capacity of Angiomax, including bioreactors and peptide synthesis lines, to meet rising demand.
- Several biotech startups explore biosimilar versions of bivalirudin, but market entry remains delayed due to regulatory challenges.
Key Takeaways
- The primary supplier in the U.S. is Novartis (original manufacturer).
- Multiple CMOs globally produce peptide-based injectables like bivalirudin.
- Patent expirations have enabled emerging markets to access generics.
- Manufacturing complexity and regulatory requirements limit rapid market entry for new suppliers.
FAQs
1. Who are the leading manufacturers of bivalirudin worldwide?
The leading manufacturer is Novartis, which markets Angiomax. Other suppliers include Biocon in India and several CMOs such as Famar, WuXi Biologics, and Lonza providing contract manufacturing services.
2. Are there generic versions of bivalirudin available?
Yes, generics became available after patent expiration around 2014 in certain markets. Availability varies by country, depending on regulatory approval.
3. What factors influence supply security for bivalirudin?
Supply security depends on manufacturing capacity, GMP compliance, patent protections, and the number of approved suppliers.
4. What are the barriers for new suppliers entering the bivalirudin market?
Barriers include peptide synthesis complexity, regulatory approval processes, GMP certification requirements, and patent rights.
5. How has market competition changed since patent expiry?
Market competition increased with the entry of generics, lowering prices and expanding access in emerging markets, while original suppliers focus on capacity expansion and new formulations.
Citations
[1] U.S. Food and Drug Administration. (2014). Bivalirudin (Angiomax) patent expiration and generic entry. Retrieved from https://www.fda.gov
